China Dealbook: TransLink leads $14m round in Uhouzz; 3D Medicines gets $101m funding

In the latest funding developments, Uhouzz Network Technology, a China-based a platform for foreign students to rent a house, has raised $14 million funding led by TransLink Capital, while 3D Medicines has raised $101 million in a new funding round led by private equity firm China Reform Holdings.

TransLink leads $14m round in Uhouzz

Uhouzz Network Technology, a China-based a platform for foreign students to rent a house, has raised $14 million in Series B round of funding led by TransLink Capital.

Existing investor New Oriental Education also participated into the round, which will be used for technology development and hiring, Liu Zhiqiang, co-founder and CTO of the company said.

Prior to this, the platform raised RMB50 million Series A round of financing led by TICO Capital and Leo Shares Fund in July 2016 and an A + round of strategic finance led by Little Station Education in December 2016.

Uhouzz provides services including renting and housing, international flights, immigration, personalized custom service and additional valuable services such as insurance, luggage transportation, airport pick-up and so on, according to its LinkedIn profile.

3D Medicines gets $101m funding

3D Medicines, a Chinese healthcare firm developing precision medicine for cancer treatment, has raised $101 million in a new funding round led by private equity firm China Reform Holdings Co., Ltd, CMN reported.

China Reform Holdings has made the investment via China State-Owned Assets Venture Investment Fund, a policy fund established last year with target size of $30 billion. ChinaEquity Group and a number of unnamed investors also participated in the round.

Headquartered in Beijing, China Reform Fund is focused on three core sectors including new generation information technology, advanced manufacturing and services, high end medical equipment and biomedicine services.

Founded in 2010, 3D Medicines develops personalized medicines according to target population’s genetic background, to increase efficacy and safety.

Also Read:

China Dealbook: THG leads $6m funding in Rokae; Bizvane, Zoomdu fundraise

China Digest: Tiger Management leads $120m round in Yunmanman; AI startup CloudWalk raises $75m Series B